CervoMed (CRVO) 12th Annual Cantor Fitzgerald Global Healthcare Conference summary

Executive introductions and company overview

• CEO has extensive R&D and clinical leadership experience in neurology and aging diseases.

• Company is focused on neflamapimod, targeting dementia with Lewy bodies (DLB) and expanding into other neurodegenerative indications.

• Positive phase II data in DLB and a clear phase III registration path agreed with global regulators.

• Additional programs include non-fluent primary progressive aphasia (PPA) and an upcoming ALS study.

Disease background and clinical strategy

• DLB is characterized by alpha-synuclein pathology, distinct from Alzheimer's, with faster progression and greater impact on daily living.

• Pure DLB patients have less neuronal loss than those with Alzheimer's co-pathology, making them more responsive to therapy.

• Blood tests for phospho-tau181 now enable accurate separation of pure DLB from mixed pathology for clinical trials.

• U.S. market opportunity is estimated at 150,000–175,000 diagnosed pure DLB patients, with similar or higher numbers in Europe and Japan.

Drug mechanism and regulatory progress

• Neflamapimod inhibits p38α, blocking neuroinflammation pathways central to DLB pathogenesis.

• The drug disrupts the link between neuroinflammation and alpha-synuclein toxicity.

• Received U.K. Innovation Passport (ILAP), reflecting high unmet need and transformative potential.

• Only 20–25% of applicants receive ILAP, highlighting selectivity.